Nat West Group PLC Biogen Inc. Transaction History

Nat West Group PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 16, 2020	SELL	$258.66 - $342.55 $168,904 - $223,685	-653 Closed	0 $0
Q1 2020 May 07, 2020	BUY	$268.85 - $341.04 $175,559 - $222,699	653 New	653 $207,000
Q4 2018 Feb 12, 2019	SELL	$278.5 - $352.75 $192,722 - $244,103	-692 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$293.51 - $383.83 $46,961 - $61,412	-160 Reduced 18.78%	692 $244,000
Q1 2018 May 14, 2018	SELL	$260.13 - $367.91 $20,810 - $29,432	-80 Reduced 8.58%	852 $233,000

Q4 2017 Feb 06, 2018	SELL	$307.64 - $344.58 $29,225 - $32,735	-95 Reduced 9.25%	932 $297,000
Q3 2017 Nov 14, 2017	SELL	$281.15 - $329.69 $2,811 - $3,296	-10 Reduced 0.96%	1,027 $322,000
Q2 2017 Aug 14, 2017	BUY	N/A	1,037	1,037 $282,000

1,047

126M

1.37M

1.35M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $33B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Nat West Group PLC, based on Form 13F filings with the SEC.

Stay updated on Nat West Group PLC with notifications on news.